Get Old originated by Pfizer in 2012 to challenge misperceptions about ageing and foster a candid conversation around aging. Get Old includes a website,, with content from notable bloggers, professional guest blogs, in addition to tools and assets from our partner businesses. The campaign is now entering its third calendar year. How effective has it been up to now? We continue to see increased engagement and positive opinions from the Get Old program. Adults exposed to statement they have made positive changes as a complete result of getting together with the site, including: 44 percent – changed their eating habits for the better 42 percent – made changes within their lives to be healthier 35 percent – started or transformed physical exercise What is the primary focus of the advertising campaign this year? In its third year Now, the program is utilizing a mix of wit and wisdom to talk about aging in a new way with the hope of engaging customers of all ages to talk about getting old and to make choices to help them age group site; it features new now, engaging, shareable articles to address #FOGO, including: a #FOGO quiz; humorous videos; educational content on topics such as health and wellness, family and human relationships, and sex and love; and new tools and resources from our several partner organizations.Two situations of isoniazid-resistant tuberculosis and three cases of rifampin-resistant tuberculosis were detected.). Conversation We found that 3 new prophylactic regimens against tuberculosis in HIV-infected adults weren’t more advanced than the control program of isoniazid therapy for 6 months. The overall rate of tuberculosis was 1.9 cases per 100 person-years, without significant difference between any of the three new regimens and the control regimen. Among HIV-contaminated people in Africa with a positive tuberculin epidermis test who aren’t getting antituberculosis treatment, the anticipated annual price of tuberculosis ranges from 5 and 10 percent.2,4,6,7 The price of tuberculosis in the control group was substantially less than anticipated also, suggesting that all the treatments found in this scholarly research performed better than regimens used in earlier African studies.10,11 The shorter, rifamycin-based regimens had higher adherence rates than did the 6-month isoniazid regimen and didn’t appear to select for drug-resistant M.